We are monitoring the impact of COVID-19 on U.S. Active Pharmaceutical Ingredients Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 11491
Share on
Share on

U.S. Active Pharmaceutical Ingredients Market Research Report – Segmented By Type of Manufacturing Process, Type of Synthesis, API Formulation, Application, Molecules and Country – Industry Size, Share, Trends & Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 11491
Pages: 90

U.S. Active Pharmaceutical Ingredients Market Size (2021 to 2026)

The U.S. Active Pharmaceutical Ingredients Market size is estimated to be growing at a CAGR of 10.24% between 2021 to 2026.

The active pharmaceutical ingredients market is projected to be majorly driven by the factors such as the prevalence of chronic diseases, the growing uptake of biopharmaceutical, and the rising importance of generics. On the other hand, growth can be attributed to the advancements in active pharmaceutical ingredient manufacturing and growing healthcare infrastructure. Over the years, U.S. has witnessed rising cardiovascular diseases, which is expected to improve the market growth. However, growing diabetes, asthma, and chronic obstructive pulmonary diseases have increased in the geriatric population across the united states.

Significantly growing drug research and development provide multiple opportunities for the manufactures to introduce advanced active pharmaceutical products. API in a drug is specifically used for treating, diagnosing, mitigating, or preventing human health problems. Also, it has a significant effect on the body's physiological functions, repairing, changing, or altering them, which is more likely to show a positive impact on the market growth. Active Pharmaceutical ingredients have a wide range of applications in the pharmaceutical industry, including oncology, central nervous system disorders, diabetes, neurological disorders, cardiovascular disease, pulmonary disease, and so on, which creates U.S. Active Pharmaceutical Ingredients Market growth.  

Favorable government policies for API development, increasing incentives, and investment by the private and government organizations in the United States are likely to increase the market growth. Since ADCs are essential and effective cancer therapy modalities used in combination with clinically active drugs and monoclonal antibodies, the development of cancer-specific APIs is expected to propel the U.S. API market even further.

Active pharmaceutical component manufacturers must make costly investments to update their manufacturing facilities to meet requirements such as c GMP, which is a significant challenge for market growth. API chemical synthesis also requires costly and rare building blocks and raw materials, further increasing API manufacturing costs.

Impact of COVID-19 on the U.S. Active Pharmaceutical Ingredients Market:

The emergence of the COVID-19 pandemic in 2020 has had a positive impact on the market. Countries and major players are producing massive quantities of ingredients to meet the demand for COVID 19 treatment. However, during the first half of 2020, the market had a downfall on U.S. active pharmaceutical ingredients market.  The virus had impacted the United States' drug supply chain and manufacturing of pharmaceutical products due to lack of workforce. However, to remain competitive in the market, large companies in the united states are introducing emerging technology and launching new products. Mergers and acquisitions, as well as innovative product growth, are examples of competitive strategies. Pfizer (US), for instance, signed a multi-year deal with Gilead Sciences Inc. in 2020 to manufacture and supply Gilead's antiviral medication (Remdesivir) for the treatment of COVID-19. Due to the COVID-19 outbreak, drug companies have redirected their models to focus on a larger consumer pool.

This research report on the U.S. active pharmaceutical ingredients market has been segmented and sub-segmented into the following categories.

By Type of Manufacturing Process:

  • Captive Manufacturing
  • Contract Manufacturing

By Type of Synthesis:

  • Synthetic
  • Biotech

By API Formulation:

  • Generic API
  • Innovative API

By Application:

  • Cardiovascular Diseases
  • Oncology
  • Neurological Disorders
  • Orthopedic Disorders
  • Respiratory
  • Gastrointestinal Disorders
  • Urology
  • Others

By Molecule:

  • Large Molecule
  • Small Molecule

By Country:

  • The United States

The United States had recorded the largest market share of active pharmaceutical ingredients in 2020 in the global market, and it is expected to continue to grow further during the forecast period. Increased technological advancements would boost the capabilities and manufacturing expertise of market players, allowing them to supply APIs in bulk to meet consumer demand, thereby propelling the active pharmaceutical ingredients (API) market. The growing prevalence of preventable chronic diseases, increased government emphasis on generic drugs, and the demand for biologics and specialty medicines contribute to the United States' vast share of the North American market. The united states market growth has significantly increased over the years as Large firms in the United States are adopting digital technologies and releasing new goods to remain competitive. Mergers and acquisitions, as well as the creation of new products, are examples of competitive strategies.

KEY MARKET PLAYERS:

Companies such as Sanofi, Bayer AG, Pfizer Inc., F. Hoffmann-La Roche AG, Abbott Laboratories, Merck & Co., Inc., Boehringer Ingelheim GmbH, GlaxoSmithKline Plc (GSK), Novartis AG, Eli Lilly and Company, and Teva Pharmaceutical Industries Ltd are playing a significant role in the U.S. active pharmaceutical ingredients market.

  1. Introduction
    1. Market Definition
    2. Study Deliverables
    3. Base Currency, Base Year and Forecast Periods
    4. General Study Assumptions
  2. Research Methodology
    1. Introduction
    2. Research Phases
        1. Secondary Research
        2. Primary Research
        3. Econometric Modelling
        4. Expert Validation
    3. Analysis Design
    4. Study Timeline
  3. Overview
    1. Executive Summary
    2. Key Inferences
    3. New Developments
  4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
    1. Market Drivers
    2. Market Restraints
    3. Key Challenges
    4. Current Opportunities in the Market
  5. Market Segmentation
    1. By Type of Manufacturing Process
      1. Captive Manufacturing
      2. Contract Manufacturing
      3. Y-o-Y Growth Analysis, By Manufacturing Process
      4. Market Attractiveness Analysis, By Manufacturing Process
      5. Market Share Analysis, By Manufacturing Process
    2. By Type of Synthesis
      1. Synthetic
      2. Biotech
      3. Y-o-Y Growth Analysis, By Type of Synthesis
      4. Market Attractiveness Analysis, By Type of Synthesis
      5. Market Share Analysis, By Type of Synthesis
    3. By API Formulation
      1. Generic API
      2. Innovative API
      3. Y-o-Y Growth Analysis, By API Formulation
      4. Market Attractiveness Analysis, By API Formulation
      5. Market Share Analysis, By API Formulation
    4. By Application
      1. Cardiovascular Diseases
      2. Oncology
      3. Neurological Disorders
      4. Orthopedic Disorders
      5. Respiratory
      6. Gastrointestinal Disorders
      7. Urology
      8. Others
      9. Y-o-Y Growth Analysis, By Application
      10.  Market Attractiveness Analysis, By Application
      11.  Market Share Analysis, By Application
    5. By Molecule
      1. Large Molecule
      2. Small Molecule
      3. Y-o-Y Growth Analysis, By Molecule
      4. Market Attractiveness Analysis, By Molecule
      5. Market Share Analysis, By Molecule
  6. Geographical Analysis
    1. Introduction    
      1. Regional Trends   
      2. Impact Analysis    
      3. Y-o-Y Growth Analysis        
        1. By Geographical Area
        2. By Product
        3. By Technology
        4. By Application
        5. By End-User
      4. Market Attractiveness Analysis      
        1. By Geographical Area
        2. By Product
        3. By Technology
        4. By Application
        5. By End-User
      5.      Market Share Analysis   
        1. By Geographical Area
        2. By Product
        3. By Technology
        4. By Application
        5. By End-User
    2. The United States
  7. Strategic Analysis
    1. PESTLE analysis
      1. Political
      2. Economic
      3. Social
      4. Technological
      5. Legal
      6. Environmental
    2. Porter’s Five analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Consumers
      3. Threat of New Entrants
      4. Threat of Substitute Products and Services
      5. Competitive Rivalry within the Industry
  8. Market Leaders' Analysis
    1. Sanofi
      1. Overview
      2. Product Analysis
      3. Strategic Evaluation and Operations
      4. Financial analysis
      5. Legal issues
      6. Recent Developments
      7. SWOT analysis
      8. Analyst View
    2. Bayer AG
    3. Pfizer Inc.
    4. F. Hoffmann-La Roche AG
    5. Abbott Laboratories
    6. Merck & Co., Inc.
    7. Boehringer Ingelheim GmbH
    8. Glaxosmithkline Plc (GSK)
    9. Novartis AG
    10. Eli Lilly and Company
    11. Teva Pharmaceutical Industries Ltd
  9. Competitive Landscape
    1. Market share analysis
    2. Merger and Acquisition Analysis
    3. Agreements, Collaborations and Joint Ventures
    4. New Product Launches
  10. Market Outlook and Investment Opportunities
  11. Appendix
    1. List of Tables
    2. List of Figures  
  • Country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped.
  • Segment-level analysis in terms of type of manufacturing process, type of synthesis, API formulation, application, molecules along with market size forecasts and estimations to detect key areas of industry growth in detail.
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics.
  • Study of the effect of exogenous and endogenous factors that affect the global market, which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis.
  • Study the microenvironment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development.
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment.
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies, and recent developments in the market by the major companies.
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis, and main conclusions.
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market.
  1. U.S. Active Pharmaceutical Ingredients Market, By Type of Manufacturing process, From 2021 to 2026 (USD Million)
  2. U.S. Captive Manufacturing Market, By Region, From 2021 to 2026 (USD Million)
  3. U.S. Contract Manufacturing Market, By Region, From 2021 to 2026 (USD Million)
  4. U.S. Active Pharmaceutical Ingredients Market, By Type of Synthesis, From 2021 to 2026 (USD Million)
  5. U.S. Synthetic Market, By Region, From 2021 to 2026 (USD Million)
  6. U.S. Biotech Market, By Region, From 2021 to 2026 (USD Million)
  7. U.S. Active Pharmaceutical Ingredients Market, By API Formulation, From 2021 to 2026 (USD Million)
  8. U.S. Generic API Market, By Region, From 2021 to 2026 (USD Million)
  9. U.S. Innovative API Market, By Region, From 2021 to 2026 (USD Million)
  10. U.S. Active Pharmaceutical Ingredients Market, By Application, From 2021 to 2026 (USD Million)
  11. U.S. Cardiovascular Diseases Market, By Region, From 2021 to 2026 (USD Million)
  12. U.S. Oncology Market, By Region, From 2021 to 2026 (USD Million)
  13. U.S. Neurological Disorders Market, By Region, From 2021 to 2026 (USD Million)
  14. U.S. Orthopaedic Disorders Market, By Region, From 2021 to 2026 (USD Million)
  15. U.S. Respiratory Market, By Region, From 2021 to 2026 (USD Million)
  16. U.S. Gastrointestinal Disorders Market, By Region, From 2021 to 2026 (USD Million)
  17. U.S. Urology Market, By Region, From 2021 to 2026 (USD Million)
  18. U.S. Others Market, By Region, From 2021 to 2026 (USD Million)
  19. U.S. Active Pharmaceutical Ingredients Market, By Molecule, From 2021 to 2026 (USD Million)
  20. U.S. Large Molecule Market, By Region, From 2021 to 2026 (USD Million)
  21. U.S. Small Molecule Market, By Region, From 2021 to 2026 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample